Pharmaceuticals (Basel) 2026 – BPC 157 Systematic Review (PMID 41754849)

Tier 2: Professional organization or credentialed expert guidance
Publisher: Pharmaceuticals (Basel) / PubMed · Published: February 12, 2026 · Accessed: August 11, 2026

Visit the source ↗

Claims this source supports

• BPC-157 is studied for tissue, tendon, and muscle repair; the 2026 systematic review describes the evidence base as predominantly preclinical (animal and lab studies) with limited clinical data.
• There is no FDA-approved BPC-157 product for any indication.
• The gray-market popularity of BPC-157 (and peptides generally) far outpaces the human clinical evidence for them.